Accuracy of the cobas EGFR Mutation Assay in Non–small‐cell Lung Cancer Compared With Three Laboratory‐developed Tests

[1]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[2]  B. Cho,et al.  Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. , 2016, Lung cancer.

[3]  H. Saji,et al.  Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases. , 2015, Clinical lung cancer.

[4]  A. Senderowicz,et al.  Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics , 2014, Clinical Cancer Research.

[5]  G. Rasi,et al.  Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union , 2014, Clinical Cancer Research.

[6]  T. Ohira,et al.  Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. , 2014, Lung Cancer.

[7]  Yongmei Yin,et al.  Clinical perspective of afatinib in non-small cell lung cancer. , 2013, Lung cancer.

[8]  T. Mitsudomi,et al.  An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  T. Nagayasu,et al.  Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer. , 2012, Clinical lung cancer.

[10]  W. Pao,et al.  Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis , 2012, Clinical Cancer Research.

[11]  K. Soejima,et al.  The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing , 2011, International Journal of Clinical Oncology.

[12]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[14]  K. Nishio,et al.  High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients , 2006, Cancer science.

[15]  Huqun,et al.  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.

[16]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[17]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[18]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[19]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[20]  Yang Zhang,et al.  Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. , 2013, Lung cancer.

[21]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[22]  S. Schuster.  Next-generation sequencing transforms today's biology , 2008, Nature Methods.